Olink® Explore 3072
A high-throughput platform offering uncompromised data quality
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The next best thing in proteomics!
Proteomics
Olink’s PEA technology has finally allowed researchers to look at differential protein expression on the highest Plex scale to date. This product will be integral in biomarker discovery and disease characterization. Their support staff is very responsive and extremely knowledgeable. I also experienced a very acceptable turnaround time from shilling samples to receiving data.
Review Date: 24 Mar 2022 | Olink Proteomics
Olink® Explore 3072 is a high-throughput protein biomarker discovery platform used to measure the concentration of thousands of human plasma proteins using minute amounts of sample. Explore 3072 comprises our entire library of validated protein assays.
How proteomics enriches early cancer detection
In this application note, Olink presents key research findings and new insights from data generated by high- plex proteomic analyses that have enriched our understanding of cancer biology and enabled the prediction of early cancer development.
Proteomics at the heart of multiomics studies
In this application note, learn how combining multiple omics technologies, with proteomics at the heart of such strategies, can give a much clearer and comprehensive picture of real-time biology, and how this will drive future healthcare development.
Revolutionizing biomarker research with Olink technology
Hear from Professor Guillaume Paré from McMaster University, as he discusses the critical shift away from the traditional 'one biomarker, one disease' paradigm. He advocates for a more dynamic view of biomarkers, particularly focusing on protein signatures that can support better disease understanding and therapy development.
Olink is paving the way with its PEA technology to support the analysis of 5–5400+ proteins simultaneously. By working with an Olink Certified Service Provider such as CRLB-GMEL headed by Professor Guillaume Paré, investigators are enabled to redefine the boundaries of medical research and gain unique insights into disease biology, aiding the identification of new therapeutic targets and biomarkers.
Population scale proteomics accelerates the search for effective new drug targets
In this video, Dr. Chris Whelan, Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project, discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success. Dr. Whelan explains how Proximity Extension Assay (PEA) technology from Olink was used to quantify these protein concentrations using innovative dual recognition, DNA-coupled methodology.
New insights into human disease that could propel drug development
The largest open-access proteogenomic dataset to date lays the groundwork for the future discovery of novel drug targets and biomarkers
The importance of protein biomarkers in drug development: A roundtable discussion
SelectScience speaks with drug discovery experts to learn how they are using protein biomarkers across different stages of the drug development process
Meet your winners in the 2022 Scientists’ Choice Awards for Life Sciences
Beckman Coulter Life Sciences, Zymo Research, and Corning Life Sciences among those recognized at AACR 2022
